SI2842573T1 - Monoclonal antibodies to Fibroblast Growth Factor receptor 2 - Google Patents
Monoclonal antibodies to Fibroblast Growth Factor receptor 2 Download PDFInfo
- Publication number
- SI2842573T1 SI2842573T1 SI200931763T SI200931763T SI2842573T1 SI 2842573 T1 SI2842573 T1 SI 2842573T1 SI 200931763 T SI200931763 T SI 200931763T SI 200931763 T SI200931763 T SI 200931763T SI 2842573 T1 SI2842573 T1 SI 2842573T1
- Authority
- SI
- Slovenia
- Prior art keywords
- mab
- binding
- growth factor
- receptor
- fibroblast growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11268608P | 2008-11-07 | 2008-11-07 | |
| US16487009P | 2009-03-30 | 2009-03-30 | |
| EP14188785.1A EP2842573B1 (en) | 2008-11-07 | 2009-11-06 | Monoclonal antibodies to Fibroblast Growth Factor receptor 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2842573T1 true SI2842573T1 (en) | 2018-01-31 |
Family
ID=42153600
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200931763T SI2842573T1 (en) | 2008-11-07 | 2009-11-06 | Monoclonal antibodies to Fibroblast Growth Factor receptor 2 |
| SI200932035T SI3290052T1 (sl) | 2008-11-07 | 2009-11-06 | Monoklonska protitelesa proti receptorju 2 fibroblastnega rastnega faktorja |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200932035T SI3290052T1 (sl) | 2008-11-07 | 2009-11-06 | Monoklonska protitelesa proti receptorju 2 fibroblastnega rastnega faktorja |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US8101723B2 (enExample) |
| EP (4) | EP2365828B1 (enExample) |
| JP (8) | JP5627591B2 (enExample) |
| KR (1) | KR101699432B1 (enExample) |
| CN (1) | CN102131524B (enExample) |
| AU (1) | AU2009313357B2 (enExample) |
| BR (1) | BRPI0917315B8 (enExample) |
| CA (3) | CA2733668C (enExample) |
| DK (3) | DK2842573T3 (enExample) |
| ES (3) | ES2523740T3 (enExample) |
| HR (2) | HRP20171640T1 (enExample) |
| HU (1) | HUE035700T2 (enExample) |
| LT (2) | LT2842573T (enExample) |
| MX (1) | MX2011000455A (enExample) |
| NO (1) | NO2842573T3 (enExample) |
| PL (3) | PL3290052T3 (enExample) |
| PT (3) | PT3290052T (enExample) |
| RU (1) | RU2546254C9 (enExample) |
| SI (2) | SI2842573T1 (enExample) |
| WO (1) | WO2010054265A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9260525B2 (en) | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| US20110059091A1 (en) * | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
| PL3290052T3 (pl) | 2008-11-07 | 2020-06-29 | Galaxy Biotech, Llc | Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów |
| US8481688B2 (en) * | 2010-05-11 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-FGFR2 antibodies |
| CN103201287B (zh) * | 2010-08-12 | 2016-04-13 | 艾托生物有限公司 | 成纤维细胞生长因子受体2的致癌异构体的抗体分子及其用途 |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AR088941A1 (es) * | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| MX2014007121A (es) * | 2011-12-14 | 2014-09-04 | Seattle Genetics Inc | Nuevos conjugados de principio activo-ligante (adc) y su uso. |
| EP2822968B1 (en) | 2012-03-08 | 2018-01-10 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
| CN104334724B (zh) | 2012-04-09 | 2020-09-01 | 第一三共株式会社 | 抗-fgfr2抗体 |
| WO2014089193A1 (en) * | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| JP6488236B2 (ja) * | 2012-12-21 | 2019-03-20 | ヤンセン バイオテツク，インコーポレーテツド | 可溶型線維芽細胞増殖因子受容体の高感度多重イムノアッセイ |
| CN103145843B (zh) * | 2013-02-20 | 2014-10-29 | 暨南大学 | 抗成纤维细胞生长因子受体的单链抗体 |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| CN105452296B (zh) * | 2013-08-01 | 2020-09-25 | 戊瑞治疗有限公司 | 无岩藻糖基化抗fgfr2iiib抗体 |
| US9931401B2 (en) * | 2013-10-08 | 2018-04-03 | Daiichi Sankyo Company, Limited | Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor |
| CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
| EP3154589A1 (en) | 2014-06-13 | 2017-04-19 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| CN104231079A (zh) * | 2014-09-12 | 2014-12-24 | 暨南大学 | 一种靶向bFGF高亲和力受体结合位点的抗体及其应用 |
| TW201642904A (zh) * | 2015-04-08 | 2016-12-16 | 第一三共股份有限公司 | 含抗ｆｇｆｒ２抗體及其他藥劑之組成物 |
| US10881734B2 (en) | 2015-04-20 | 2021-01-05 | Daiichi Sankyo Company, Limited | Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof |
| RU2638457C2 (ru) * | 2015-09-28 | 2017-12-13 | Общество С Ограниченной Ответственностью "Онкомакс" | Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител |
| RU2745707C2 (ru) | 2015-11-23 | 2021-03-30 | Файв Прайм Терапьютикс, Инк. | Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| LT3624837T (lt) | 2017-05-16 | 2025-10-10 | Anti-fgfr2 antikūnai derinyje su chemoterapijos agentais vėžio gydymui | |
| MX2019014504A (es) | 2017-06-02 | 2020-07-20 | Merck Patent Gmbh | Inmunoglobulinas de union a agrecano. |
| US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| EP3700568A4 (en) | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| WO2019084067A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | ANTI-CD117 ANTIBODIES AND METHODS OF USE |
| US12460000B2 (en) | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
| UA130250C2 (uk) | 2018-10-05 | 2025-12-31 | Файв Прайм Терапьютикс, Інк. | Рідкий фармацевтичний склад та композиція на основі антитіла до fgfr2 |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| WO2021129656A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| CN114846029A (zh) * | 2019-12-24 | 2022-08-02 | 迪哲(江苏)医药股份有限公司 | 新颖抗fgfr2b抗体 |
| EP4161566A4 (en) * | 2020-06-03 | 2024-06-12 | The Broad Institute, Inc. | ANTAGONISTIC BIPARATOPIC ANTIBODIES SPECIFICALLY BINDING FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USE THEREOF |
| CA3190569A1 (en) | 2020-10-22 | 2022-04-28 | Christopher Daly | Anti-fgfr2 antibodies and methods of use thereof |
| CN116847876A (zh) * | 2020-12-29 | 2023-10-03 | 深圳福沃药业有限公司 | 抗fgfr2抗体及其用途 |
| WO2023056916A1 (zh) * | 2021-10-08 | 2023-04-13 | 深圳福沃药业有限公司 | Adcc增强型抗fgfr2抗体及其用途 |
| TW202342527A (zh) | 2022-02-25 | 2023-11-01 | 美商安進公司 | 鱗狀非小細胞肺癌之治療 |
| WO2024067876A1 (en) * | 2022-09-30 | 2024-04-04 | 3H Pharmaceuticals Co., Ltd. | Anti-fgfr2b antibodies and uses thereof |
| CN118852431A (zh) * | 2023-04-28 | 2024-10-29 | 武汉人福创新药物研发中心有限公司 | 抗FGFR2b单抗 |
| EP4714976A1 (en) * | 2023-05-19 | 2026-03-25 | Sunshine Lake Pharma Co., Ltd. | Anti-fgfr2 antibody and use thereof |
| CN119855835A (zh) * | 2023-06-13 | 2025-04-18 | 南京维立志博生物科技股份有限公司 | 基于共同轻链产生双特异性抗体的方法 |
| WO2025130905A1 (zh) * | 2023-12-18 | 2025-06-26 | 山东先声生物制药有限公司 | 抗FGFR2b抗体-药物缀合物及其应用 |
| WO2025218662A1 (zh) * | 2024-04-16 | 2025-10-23 | 杭州中美华东制药有限公司 | 抗成纤维细胞生长因子受体2b的抗体及其用途 |
| TW202547875A (zh) * | 2024-05-09 | 2025-12-16 | 大陸商正大天晴藥業集團股份有限公司 | 靶向成纖維細胞生長因子受體2IIIb的抗體及其應用 |
| WO2026007196A1 (zh) * | 2024-07-02 | 2026-01-08 | 安博泰克药业有限公司 | 特异性结合FGFR2b的抗体及其与药物的缀合物 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP3039802B2 (ja) | 1989-07-06 | 2000-05-08 | ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア | 繊維芽細胞成長因子のための受容体 |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| EP0723556A4 (en) * | 1993-10-14 | 2003-03-19 | Immunex Corp | FAS ANTAGONISTS AND THEIR APPLICATIONS |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| AU3494397A (en) | 1996-06-18 | 1998-01-07 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fibroblast growth factor receptor activating gene i and related compositions and methods |
| US20030143676A1 (en) | 1999-03-25 | 2003-07-31 | Genesis Research And Development Corporation Limited | Fibroblast growth factor receptors and methods for their use |
| IL145941A (en) * | 1999-04-28 | 2007-08-19 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| JP2001302699A (ja) | 2000-04-17 | 2001-10-31 | Nichirei Corp | ヒトｋｇｆｒに対する抗体 |
| US20020115603A1 (en) | 2000-06-22 | 2002-08-22 | Chiron Corporation | Methods and compositions for the treatment of peripheral artery disease |
| WO2002100348A2 (en) * | 2001-06-13 | 2002-12-19 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| JP2005530687A (ja) | 2002-01-31 | 2005-10-13 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Ｆｇｆｒアゴニスト |
| KR100493460B1 (ko) * | 2002-08-29 | 2005-06-07 | 재단법인서울대학교산학협력재단 | 암 세포에서 발현되는 ｆｇｆｒ2 이성체 |
| US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| NZ544797A (en) | 2003-07-18 | 2011-04-29 | Amgen Fremont Inc | Specific antibodies that bind HGF and neutralise binding of HGF to met |
| WO2005066211A2 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| US7872016B2 (en) | 2004-05-25 | 2011-01-18 | Yale University | Method for treating skeletal disorders resulting from FGFR malfunction |
| US7890267B2 (en) | 2006-03-31 | 2011-02-15 | Ordway Research Institute | Prognostic and diagnostic method for cancer therapy |
| AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| EP2018442A2 (en) * | 2006-05-12 | 2009-01-28 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
| JP4560582B2 (ja) | 2006-06-02 | 2010-10-13 | アベオ ファーマシューティカルズ， インコーポレイテッド | 肝細胞成長因子（ｈｇｆ）結合蛋白質 |
| SG158112A1 (en) | 2006-06-02 | 2010-01-29 | Aveo Pharmaceuticals Inc | Hepatocyte growth factor (hgf) binding proteins |
| WO2007144893A2 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| HUE028379T2 (en) | 2006-09-29 | 2016-12-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| US8394927B2 (en) * | 2006-11-03 | 2013-03-12 | U3 Pharma Gmbh | FGFR4 antibodies |
| AU2008230880B2 (en) * | 2007-03-23 | 2014-04-24 | The Translational Genomics Research Institute | Method of diagnosing, classifying and treating endometrial cancer and precancer |
| WO2009052830A1 (en) | 2007-10-22 | 2009-04-30 | Genmab A/S | Novel antibody therapies |
| US20110059091A1 (en) | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| PL3290052T3 (pl) | 2008-11-07 | 2020-06-29 | Galaxy Biotech, Llc | Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów |
| US20120301482A1 (en) | 2009-08-25 | 2012-11-29 | National Jewish Health | Methods and compositions for treatment of lung injury |
-
2009
- 2009-11-06 PL PL17191118T patent/PL3290052T3/pl unknown
- 2009-11-06 DK DK14188785.1T patent/DK2842573T3/en active
- 2009-11-06 WO PCT/US2009/063647 patent/WO2010054265A2/en not_active Ceased
- 2009-11-06 ES ES09825523.5T patent/ES2523740T3/es active Active
- 2009-11-06 CA CA2733668A patent/CA2733668C/en active Active
- 2009-11-06 BR BRPI0917315A patent/BRPI0917315B8/pt active IP Right Grant
- 2009-11-06 US US12/614,282 patent/US8101723B2/en active Active
- 2009-11-06 LT LTEP14188785.1T patent/LT2842573T/lt unknown
- 2009-11-06 MX MX2011000455A patent/MX2011000455A/es active IP Right Grant
- 2009-11-06 JP JP2011534932A patent/JP5627591B2/ja active Active
- 2009-11-06 RU RU2011141890/10A patent/RU2546254C9/ru active
- 2009-11-06 PT PT171911183T patent/PT3290052T/pt unknown
- 2009-11-06 SI SI200931763T patent/SI2842573T1/en unknown
- 2009-11-06 DK DK09825523.5T patent/DK2365828T3/en active
- 2009-11-06 ES ES14188785.1T patent/ES2646168T3/es active Active
- 2009-11-06 SI SI200932035T patent/SI3290052T1/sl unknown
- 2009-11-06 PT PT141887851T patent/PT2842573T/pt unknown
- 2009-11-06 EP EP09825523.5A patent/EP2365828B1/en active Active
- 2009-11-06 CN CN200980132269.2A patent/CN102131524B/zh active Active
- 2009-11-06 EP EP17191118.3A patent/EP3290052B1/en active Active
- 2009-11-06 CA CA3287843A patent/CA3287843A1/en active Pending
- 2009-11-06 AU AU2009313357A patent/AU2009313357B2/en active Active
- 2009-11-06 KR KR1020117002577A patent/KR101699432B1/ko active Active
- 2009-11-06 PL PL09825523T patent/PL2365828T3/pl unknown
- 2009-11-06 PL PL14188785T patent/PL2842573T3/pl unknown
- 2009-11-06 LT LTEP17191118.3T patent/LT3290052T/lt unknown
- 2009-11-06 PT PT98255235T patent/PT2365828E/pt unknown
- 2009-11-06 DK DK17191118.3T patent/DK3290052T3/da active
- 2009-11-06 ES ES17191118T patent/ES2770134T3/es active Active
- 2009-11-06 NO NO14188785A patent/NO2842573T3/no unknown
- 2009-11-06 EP EP19193727.5A patent/EP3783024A1/en active Pending
- 2009-11-06 HU HUE14188785A patent/HUE035700T2/en unknown
- 2009-11-06 EP EP14188785.1A patent/EP2842573B1/en active Active
- 2009-11-06 CA CA3166399A patent/CA3166399C/en active Active
-
2011
- 2011-10-28 US US13/284,838 patent/US8603987B2/en active Active
-
2013
- 2013-11-04 US US14/071,520 patent/US9382324B2/en active Active
-
2014
- 2014-06-04 JP JP2014115617A patent/JP6342223B2/ja active Active
-
2016
- 2016-06-02 US US15/172,033 patent/US9834609B2/en active Active
- 2016-08-03 JP JP2016152670A patent/JP6445496B2/ja active Active
-
2017
- 2017-08-10 US US15/674,385 patent/US10138301B2/en active Active
- 2017-10-26 HR HRP20171640TT patent/HRP20171640T1/hr unknown
-
2018
- 2018-10-18 US US16/164,530 patent/US10689448B2/en active Active
- 2018-11-29 JP JP2018223183A patent/JP6661734B2/ja active Active
-
2020
- 2020-01-20 HR HRP20200090TT patent/HRP20200090T1/hr unknown
- 2020-02-06 JP JP2020018719A patent/JP6960485B2/ja active Active
- 2020-05-05 US US16/867,398 patent/US20200347141A1/en not_active Abandoned
-
2021
- 2021-10-11 JP JP2021166672A patent/JP7301106B2/ja active Active
-
2023
- 2023-03-10 US US18/182,242 patent/US20230242650A1/en active Pending
- 2023-06-20 JP JP2023100475A patent/JP2023116746A/ja active Pending
-
2024
- 2024-11-05 JP JP2024193584A patent/JP2025032085A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tóth et al. | The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity | |
| CN104379602B (zh) | 具有条件活性的抗表皮生长因子受体抗体及其使用方法 | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| SI2719708T1 (en) | Material and methods for treating or preventing HER-3-related diseases | |
| JP2018534933A5 (enExample) | ||
| RU2011141890A (ru) | Моноклональные антитела к рецептору 2 фактора роста фибробластов | |
| SI2342234T1 (en) | MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL | |
| JP2007535895A5 (enExample) | ||
| RU2011144312A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА | |
| HRP20240240T1 (hr) | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice | |
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| GEP20125398B (en) | Human monoclonal antibodies to activin receptor-like kinase-1 | |
| JP2020514310A5 (enExample) | ||
| TW200720289A (en) | Antibodies against CCR5 and uses thereof | |
| JP2014240385A5 (enExample) | ||
| WO2010005566A3 (en) | Notch-binding agents and antagonists and methods of use thereof | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| EA201100918A1 (ru) | Антитела против инсулиноподобных факторов роста | |
| JP2009522316A5 (enExample) | ||
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| RU2011137369A (ru) | Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента | |
| WO2008091641A3 (en) | Compositions and methods for diagnosing and treating cancer | |
| RU2012154339A (ru) | НОВОЕ АНТИТЕЛО ПРОТИВ c-Met | |
| IL239981B2 (en) | Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer | |
| CN106459212A (zh) | 结合erbb‑2和erbb‑3的抗体 |